Rare Earth Elements Market Projected to Reach $10.44 Billion by 2030

The global rare earth elements market is projected to grow to $10.44B by 2030, with North America as the fastest-growing region. Tactical Resources Corp. (TTREO) announced plans to advance its Peak Project in Texas, focusing on heavy rare earth elements. The company reported initial metallurgical results and strategic agreements for the project. TTREO's shares began trading on Nasdaq in August 2026.

Original reporting
Published Sep 22, 2026, 1:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Rare Earth Elements Market Projected to Reach $10.44 Billion by 2030 — source image
Decision brief

The 30-second read

$TREOBullishMed
01

Why it matters

Tactical's new agreements and test results could attract capital and improve its valuation amid tightening U.S. policy on rare‑earth imports.

02

Market read

Micro‑cap rare‑earth developer receives fresh project news, aligning with broader sector growth expectations.

03

What to watch

Regulatory licensing and environmental permitting could delay commercialization.

Relevance 6/10Novelty 6/10Timing: post‑Trump security agreement announcement

Background

The article discusses a market forecast for rare‑earths and details Tactical Resources' recent project updates and agreements.

Company-level read

Ticker impact

$TREOBullishMedium confidence
Context

Tactical Resources announced new purchase agreements and an option to acquire Sierra Blanca Quarry, and reported heavy‑rare‑earth test results.

Expected impact

Potential upside of 10‑15% over the next weeks if financing follows.

Evidence & confidence

New agreements and test data are primary disclosures for a micro‑cap, but scale is limited.

Market effects

Highlights growing U.S. focus on domestic rare‑earth supply, benefiting the sector.

May increase investor interest in North American rare‑earth producers.

Signals potential shift in heavy‑rare‑earth pricing away from China.

Counterpoint

Project is early‑stage with no proven reserves; risks may outweigh short‑term upside.

Key entities

  • Tactical Resources Corp.

    U.S. rare‑earth developer listed on Nasdaq (TREO).

Related articles

$NOWMed

ServiceNow Sees AI Usage Surge as It Raises Annual Contract Value Target to $1.7 Billion

ServiceNow (NYSE: NOW) reported a surge in AI usage, raising its annual contract value target to $1.7 billion. The company is shifting towards consumption-based pricing and expanding AI capabilities across its product tiers. ServiceNow's AI tools aim to reach budgets beyond traditional IT spending, with potential to augment worker productivity. The company is also focusing on AI governance and supporting customers using other interfaces.

$VNRXMed

VolitionRx reports clinical progress across diagnostic platform

VolitionRx (VNRX) reported progress in its Nu.Q diagnostic platform, with high sensitivity and specificity in detecting cancers. Its Nu.Q NETs test is part of a €6.3M French program. The company saw a 134% revenue increase, reduced operating losses, and is in licensing discussions. It also expanded a supply agreement with Fujifilm Vet Systems for a feline cancer test.

$ACADMed

Acadia presents additional data on Alzheimer’s psychosis drug

Acadia Pharmaceuticals (NASDAQ:ACAD) presented additional data from its Phase 2 RADIANT trial of remlifanserin for Alzheimer’s disease psychosis, showing consistent efficacy signals at the 60 mg dose. The drug previously missed its primary endpoint but achieved nominal significance on key secondary endpoints. The company continues Phase 3 trials and is also investigating the drug for Lewy body dementia psychosis.

$VERUMed

Veru presents data on enobosarm for obesity treatment

Veru Inc. (VERU) presented Phase 2b QUALITY study data at ObesityWeek 2026, showing enobosarm 3mg plus semaglutide helped patients aged 65+ with obesity gain lean mass and maintain physical function. The Phase 2b PLATEAU trial, with 239 patients, is ongoing, with interim data expected in Q1 2027. Veru has a clinical supply agreement with Novo Nordisk and a U.S. patent for the combination therapy.

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.